Han Zhong, Guo Jianmin, Meng Feibiao, Liao Haifeng, Deng Yinghua, Huang Yuankeng, Lei Xialing, Liang Chun, Han Richou, Yang Wei
Guangdong Key Laboratory of Animal Conservation and Resource Utilization, Guangdong Public Laboratory of Wild Animal Conservation and Utilization, Institute of Zoology, Guangdong Academy of Sciences, Guangzhou, Guangdong, China.
Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, Guangdong Engineering Research Center for Innovative Drug Evaluation and Research, Guangzhou, Guangdong, China.
Evid Based Complement Alternat Med. 2021 Jun 18;2021:6610793. doi: 10.1155/2021/6610793. eCollection 2021.
Forsythin is the main ingredient of and is widely used in treatment of fever, viral cold, gonorrhea, and ulcers clinically. This study aimed to evaluate the potential genetic toxicity of forsythin and its safety for human use.
Based on the Good Laboratory Practice regulations and test guidelines, the genetic toxicity of forsythin was assessed by the Ames test, chromosome aberration (CA) test, and bone marrow micronucleus (MN) test in vivo. In the Ames test, five strains of were exposed to different concentrations of forsythin in the presence or absence of the S9 mixture, and then, the number of His + revertant colonies was counted. In the CA test, Chinese hamster lung (CHL) fibroblast cells were treated with different concentrations of forsythin, mitomycin C, or cyclophosphamide in the presence or absence of the S9 mixture, and the chromosomal aberrations were determined. In the MN test, bone marrow was isolated from the mice with different treatments, and the ratios of polychromatic erythrocytes (PCE) and erythrocytes (PCE/(PCE + NCE)) were measured. Finally, beagle dogs were divided into four groups (negative control, low dose, medium dose, and high dose groups), and then, a telemetry system was used to evaluate the safe use of forsythin.
Ames test results showed that the number of colonies in all test strains with different treatments showed no significantly dose-dependent increase in the presence or absence of the S9 mixture ( > 0.05). In the CA test, the number of cells with aberrations in the CHL fibroblast cells treated with low, medium, and high doses of forsythin for 24/48 h in the absence of the S9 mixture was, respectively, 5.0/2.5, 4.5/1.5, and 5.0/5.0, and in the presence of the S9 mixture, the number was, respectively, 5.0, 5.0, and 4.5. These results showed that there was no significant difference compared to the negative control group either in the presence (2.0) or in the absence (4.0/2.5 for 24/48 h) of the S9 mixture ( > 0.05). The MN test showed that the values of PCE/(PCE + NCE) in the negative, positive controls, and forsythin treatment groups were all more than 20%, which indicated that forsythin had no cytotoxicity. Additionally, no significant toxicological effects of forsythin on blood pressure, respiration, temperature, electrocardiogram, and other physiological indicators in the conscious beagle dogs of different groups were observed by the telemetry method.
Our findings showed that forsythin has low probability of genetic toxicity and no significant toxicological effects, which implied that forsythin is suitable for further development and potential application.
连翘苷是连翘的主要成分,临床上广泛用于治疗发热、病毒性感冒、淋病和溃疡。本研究旨在评估连翘苷的潜在遗传毒性及其对人体使用的安全性。
根据良好实验室规范和测试指南,通过艾姆斯试验、染色体畸变(CA)试验和体内骨髓微核(MN)试验评估连翘苷的遗传毒性。在艾姆斯试验中,将五株鼠伤寒沙门氏菌在有或无S9混合物的情况下暴露于不同浓度的连翘苷,然后计数His+回复突变菌落的数量。在CA试验中,将中国仓鼠肺(CHL)成纤维细胞在有或无S9混合物的情况下用不同浓度的连翘苷、丝裂霉素C或环磷酰胺处理,并确定染色体畸变情况。在MN试验中,从不同处理的小鼠中分离骨髓,测量多染性红细胞(PCE)与红细胞的比例(PCE/(PCE+NCE))。最后,将比格犬分为四组(阴性对照组、低剂量组、中剂量组和高剂量组),然后使用遥测系统评估连翘苷的安全使用情况。
艾姆斯试验结果表明,在有或无S9混合物的情况下,所有不同处理的测试菌株中的菌落数均未显示出明显的剂量依赖性增加(P>0.05)。在CA试验中,在无S9混合物的情况下,用低、中、高剂量连翘苷处理24/48小时的CHL成纤维细胞中出现畸变的细胞数分别为5.0/2.5、4.5/1.5和5.0/5.0,在有S9混合物的情况下,该数字分别为5.0、5.0和4.5。这些结果表明,与阴性对照组相比,在有(2.0)或无(24/48小时为4.0/2.5)S9混合物的情况下均无显著差异(P>0.05)。MN试验表明,阴性对照组、阳性对照组和连翘苷处理组的PCE/(PCE+NCE)值均超过20%,这表明连翘苷没有细胞毒性。此外,通过遥测方法未观察到连翘苷对不同组清醒比格犬的血压、呼吸、体温、心电图和其他生理指标有明显的毒理学影响。
我们的研究结果表明,连翘苷具有较低的遗传毒性概率且无明显的毒理学影响,这意味着连翘苷适合进一步开发和潜在应用。